Pharmacological and biochemical insights into lead-induced hepatotoxicity: Pathway interplay and the protective effects of arbutin via the oral and intraperitoneal routes in silico and in vivo
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112968 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Alzahraa Ahmed Elhemiely und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Egyptian Drug Authority, Cairo, Egypt. Electronic address: alzahraaelhemiely@gmail.com. Hauptthemen laut MEDLINE: Arbutin, Chemical and Drug Induced Liver Injury, Sirtuin 1, Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 102 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Lead acetate (PbAc), a hazardous heavy metal, poses significant threats to human health and the environment because of widespread industrial exposure. PbAc exposure leads to liver injury primarily through oxidative stress and the disruption of key regulatory pathways. Understanding these mechanisms and exploring protective agents are vital for mitigating PbAc-induced hepatotoxicity. Therefore, we aimed to investigate the molecular pathways implicated in PbAc-induced liver damage, focusing on Sirt-1, Nrf2 (HO-1, NQO1, and SOD), Akt-1/GSK3β, m-TOR, and P53. Additionally, we aimed to assess the hepatoprotective effects of arbutin, which is administered orally and intraperitoneally, to determine the most effective delivery method. METHODOLOGY: In silico analyses were conducted to identify relevant protein networks associated with Sirt-1 and AKT-1/GSK-3B pathways. The pharmacodynamic properties of arbutin were examined, followed by molecular docking studies to elucidate its interactions with the selected protein network. In vivo preclinical studies were carried out on adult male rats randomly assigned to 6 different treatment groups, including PbAc exposure and PbAc exposure treated with arbutin either orally or intraperitoneally. RESULTS: PbAc exposure led to hepatic oxidative stress, as evidenced by elevated MDA levels and SIRT-1 inhibition, disrupting antioxidant pathways and activating antiautophagic and proapoptotic pathways, ultimately resulting in hepatocyte necrosis. Both oral and intraperitoneal arbutin administration effectively modifed these effects, with intraperitoneal delivery showing superior efficacy in mitigating PbAc-induced histological, immunological, and biochemical alterations. CONCLUSION: This study provides insights into the molecular mechanisms underlying PbAc-induced liver injury and highlights the hepatoprotective potential of arbutin. These findings suggest that arbutin, particularly when administered intraperitoneally, holds promise as a therapeutic agent for combating PbAc-induced hepatotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Egyptian Drug Authority, Cairo, Egypt. Electronic address: alzahraaelhemiely@gmail.com.
- Department of Biochemistry, Faculty of Pharmacy, Sohag University, Sohag, Egypt. Electronic address: Alshaymaa.darwish@pharm.sohag.edu.eg.
Zitieren
APA
Elhemiely, A. A., & Darwish, A. (2024). Pharmacological and biochemical insights into lead-induced hepatotoxicity: Pathway interplay and the protective effects of arbutin via the oral and intraperitoneal routes in silico and in vivo. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112968
Vancouver
Elhemiely AA, Darwish A. Pharmacological and biochemical insights into lead-induced hepatotoxicity: Pathway interplay and the protective effects of arbutin via the oral and intraperitoneal routes in silico and in vivo. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112968
BibTeX
@article{Elhemiely2024,
author = {Elhemiely, Alzahraa Ahmed and Darwish, Alshaymaa},
title = {Pharmacological and biochemical insights into lead-induced hepatotoxicity: Pathway interplay and the protective effects of arbutin via the oral and intraperitoneal routes in silico and in vivo},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112968}
}
EUVIMED